Funded by the European Commission’s 7th Framework Programme, Eurocanplatform is a pioneering project led by The Karolinska Institute that comprises…
news
Marking the 17th International Symposium in the annual series of prestigious meetings organized by the Fritz-Bender Foundation, we are delighted…
Aleix Prat, Principal Investigator of VHIO´s Translational Genomics Group, has been awarded a grant amounting to 450.000 U.S. dollars (345.000…
VHIO Communications talks to Josep Villanueva, PI of VHIO´s Tumour Biomarkers Group, about the latest developments in tumour biomarkers and…
Fulfilling the requirements of the standard ISO 9001:2008, VHIO is one of the few research institutes in Europe to have…
The Association for International Cancer Research (AICR) – now rebranded as Worldwide Cancer Research – has awarded one of its prestigious…
David Collingridge, Editor-in-Chief of The Lancet Oncology will deliver the next in VHIO´s Meet the Editor series of talks: Insights…
This year´s annual Fero Foundation (Fundación de Investigación Oncológica) Grant for Translational Research and the very first Fero/J.P. Morgan Private…
Inés Gasén was diagnosed with breast cancer during her pregnancy – not only naturally provoking fear and uncertainty for her…
- Much of the on-going research in prostate cancer focuses on patients suffering disease relapse through resistance to conventional hormone therapy. Castration-resistant prostate cancer (CRPC) accounts for between 20 and 30% of all prostate cancers.
- With significant advances in the treatment of CRPC over recent years, the life expectancy of patients has increased from 12 months in 2004, to 3 – 4 years today.
- A half-day workshop, organised by the Vall d’ Hebron Institute of Oncology (VHIO), attended by renowned experts within the field, will update on the latest advances in prostate cancer, which has the highest incidence of all cancers in men.
